SCHEMBL157707

SCHEMBL157707

[c]1ncc2ncncc2n1

nearest known ligand 0.35

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL127479 0.77 EGFR (0.50) EGFR
SCHEMBL4424448 0.75 EGFR (0.43) EGFR
SCHEMBL28003243 0.74 EGFR (0.48) EGFR
SCHEMBL29961230 0.68 RPS6KA5 (0.44) EGFR
SCHEMBL2393994 0.68 RPS6KA5 (0.44) EGFR
SCHEMBL7738438 0.67 EGFR (0.36) EGFR
SCHEMBL153747 0.67 ALDH1A1 (0.43)
SCHEMBL3934318 0.67 EGFR (0.39) EGFR
SCHEMBL159794 0.67 EGFR (0.34) EGFR
SCHEMBL7738436 0.66 EGFR (0.35) EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 650 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024106781-A1 LIPID COMPOUND AND COMPOSITION FOR DELIVERY OF ACTIVE SUBSTANCE 한국생명공학연구원 2024-05-23 WO claimed
US-20230382905-A1 MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY EVOTEC INTERNATIONAL GMBH (DE) 2023-11-30 US claimed
US-20230357268-A1 PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION NEUSCO BIOTECH LIMITED (CN) 2023-11-09 US claimed
US-20230271980-A1 PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION NEUSCO BIOTECH LIMITED (CN) 2023-08-31 US claimed
EP-4232154-A1 MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY Evotec International GmbH (DE) 2023-08-30 EP claimed
US-20230242532-A1 TETRACYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF NEUSCO BIOTECH LIMITED (CN) 2023-08-03 US claimed
US-20230212168-A1 ENDOCYCLIC PYRIMIDINONE COMPOUNDS, AND PREPARATION METHODS, COMPOSITIONS AND USE THEREOF NEUSCO BIOTECH LIMITED (CN) 2023-07-06 US claimed
EP-4180436-A1 TRICYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF Neusco Biotech Limited (CN) 2023-05-17 EP claimed
EP-4174070-A1 TRICYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF Neusco Biotech Limited (CN) 2023-05-03 EP claimed
EP-4151638-A1 BRIDGED CYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, COMPOSITION CONTAINING SAME AND USE THEREOF Neusco Biotech Limited (CN) 2023-03-22 EP claimed
US-20150005232-A1 INDAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) 2015-01-01 US claimed
WO-2014039831-A1 SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-03-13 WO claimed
US-20110306597-A1 Nicotinamide Derivatives CRAWFORTH JAMES MICHAEL (GB) 2011-12-15 US claimed
EP-1606255-B1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB CO (US) 2009-11-11 EP claimed
US-20080114052-A1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2008-05-15 US claimed
US-7338947-B2 Cyclic derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB CO. (US) 2008-03-04 US claimed
US-20070032541-A1 Cyclic derivatives as modulators of chemokine receptor activity CHERNEY ROBERT J 2007-02-08 US claimed
US-20040186140-A1 Cyclic derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY 2004-09-23 US claimed
US-6784174-B1 INHIBITORS OF THE PRODUCTION OF CYTOKINES SUCH AS TNF ASTRAZENECA AB (SE) 2004-08-31 US claimed
EP-1165566-B1 PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASE ASTRAZENECA AB (SE) 2003-08-20 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212168-A1 ENDOCYCLIC PYRIMIDINONE COMPOUNDS, AND PREPARATION METHODS, COMPOSITIONS AND USE THEREOF PLA2G1B, PLA2G5, PLA2G4B EGFR 2847/4885
US-20080114052-A1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CCL11, CCL2, CCR1 EGFR 1749/4885
US-20040186140-A1 Cyclic derivatives as modulators of chemokine receptor activity CCL11, CCR1, CCL2 EGFR 1758/4885
US-20150005232-A1 INDAZOLE DERIVATIVES GPR119, INSR, INSRR EGFR 3677/4885
US-20230382905-A1 MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY AVPR1B, CRH, CRHR1 EGFR 4003/4885
US-20070032541-A1 Cyclic derivatives as modulators of chemokine receptor activity CCL11, CCL2, CCR1 EGFR 1749/4885
US-20110306597-A1 Nicotinamide Derivatives NNT, NAMPT, NQO1 EGFR 4156/4885
US-20230242532-A1 TETRACYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF PLA2G1B, PLA2G5, PLA2G7 EGFR 4426/4885
US-20230271980-A1 PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION PLA2G1B, PLA2G4B, PLA2G4A EGFR 4299/4885
US-20230357268-A1 PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION PLA2G1B, PLA2G4B, PLA2G5 EGFR 4391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.